Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1Advanced Solid Tumors 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × sapacitabine × Clear all
NCT00999401 2021-12-22

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Cyclacel Pharmaceuticals, Inc.

Phase 1 Completed
103 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00380653 2021-12-13

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

Cyclacel Pharmaceuticals, Inc.

Phase 1 Completed
47 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡